Stock BIM BIOMÉRIEUX
Add to a list
To use this feature you must be a member
Log inSign up

Financials bioMérieux

Equities

BIM

FR0013280286

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris
Other stock markets
 16:35:04 26/04/2024 BST 		5-day change 1st Jan Change
101.5 EUR +2.01% Intraday chart for bioMérieux +1.96% +0.89%
04-26 BioMérieux: share price rises, analyst remains Buy CF
04-26 BIOMÉRIEUX : Berenberg raises its target CF

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,371 13,654 14,780 11,591 11,883 11,993 - -
Enterprise Value (EV) 1 9,689 13,746 14,439 11,544 11,717 11,685 11,506 11,424
P/E ratio 34.5 x 33.8 x 24.7 x 25.6 x 33.4 x 26.1 x 23.2 x 20 x
Yield 0.48% 0.54% 0.68% 0.87% 0.84% 0.86% 0.99% 1.15%
Capitalization / Revenue 3.5 x 4.38 x 4.38 x 3.23 x 3.23 x 3.07 x 2.86 x 2.62 x
EV / Revenue 3.62 x 4.41 x 4.28 x 3.22 x 3.19 x 2.99 x 2.74 x 2.5 x
EV / EBITDA 16.8 x 16.7 x 14 x 13.4 x 14.2 x 13.3 x 11.9 x 10.4 x
EV / FCF 71.6 x 45 x 27.7 x 59.1 x 102 x 26.6 x 27.7 x 22.4 x
FCF Yield 1.4% 2.22% 3.61% 1.69% 0.98% 3.77% 3.61% 4.46%
Price to Book 4.27 x 5.62 x 4.75 x - 3.19 x 2.9 x 2.64 x 2.41 x
Nbr of stocks (in thousands) 118,101 118,316 118,336 118,374 118,124 118,160 - -
Reference price 2 79.35 115.4 124.9 97.92 100.6 101.5 101.5 101.5
Announcement Date 26/02/20 24/02/21 02/03/22 07/03/23 14/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,675 3,118 3,376 3,589 3,675 3,903 4,194 4,578
EBITDA 1 577.9 823.5 1,032 864.2 827 881.9 968.3 1,097
EBIT 1 370.7 595.1 784.3 587.2 439 596.6 670 762.3
Operating Margin 13.86% 19.08% 23.23% 16.36% 11.95% 15.29% 15.97% 16.65%
Earnings before Tax (EBT) 1 347.5 524.1 773.8 580.6 437.3 586.5 666.8 781.1
Net income 1 272.8 404.4 601.1 452.4 358 470.4 527.5 617.8
Net margin 10.2% 12.97% 17.8% 12.6% 9.74% 12.05% 12.58% 13.49%
EPS 2 2.300 3.410 5.060 3.820 3.010 3.887 4.366 5.069
Free Cash Flow 1 135.4 305.3 521 195.3 115.3 440 415.4 509.5
FCF margin 5.06% 9.79% 15.43% 5.44% 3.14% 11.28% 9.9% 11.13%
FCF Conversion (EBITDA) 23.43% 37.07% 50.47% 22.6% 13.94% 49.9% 42.9% 46.43%
FCF Conversion (Net income) 49.63% 75.49% 86.67% 43.17% 32.21% 93.56% 78.74% 82.48%
Dividend per Share 2 0.3800 0.6200 0.8500 0.8500 0.8500 0.8700 1.003 1.167
Announcement Date 26/02/20 24/02/21 02/03/22 07/03/23 14/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q4 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2
Net sales 1 1,400 1,476 1,642 1,574 924.2 820.9 1,658 902 1,029 1,931 864.3 1,770 898.4 1,006 - 965.2 912.5 1,878 955.1 1,101 2,056
EBITDA - - - - - - - - - - - - - - - - - - - - -
EBIT 181.5 244.1 351 365.8 - - 297.1 - - 290.1 - 207.8 - - 231.2 - - 264.5 - - 321
Operating Margin 12.97% 16.54% 21.38% 23.24% - - 17.92% - - 15.02% - 11.74% - - - - - 14.09% - - 15.61%
Earnings before Tax (EBT) - - 304.7 358.5 - - - - - 289.1 - - - - - - - 261.8 - - 318.3
Net income 132.3 172.9 231.5 277.1 - - 228 - - 224.4 - - - - - - - 207 - - 251.7
Net margin 9.45% 11.71% 14.1% 17.6% - - 13.75% - - 11.62% - - - - - - - 11.02% - - 12.24%
EPS 1.110 - 1.950 2.330 - - - - - 1.890 - - - - - - - 1.740 - - 2.120
Dividend per Share - - - - - - - - - - - - - - - - - - - - -
Announcement Date 26/02/20 02/09/20 24/02/21 01/09/21 02/03/22 31/08/22 31/08/22 26/10/22 07/03/23 07/03/23 31/08/23 31/08/23 14/12/23 14/03/24 14/03/24 - - - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 317 92.1 - - - - - -
Net Cash position 1 - - 341 47 166 308 487 569
Leverage (Debt/EBITDA) 0.5491 x 0.1118 x - - - - - -
Free Cash Flow 1 135 305 521 195 115 440 415 510
ROE (net income / shareholders' equity) 13.2% 17.4% 21.6% 13.5% 9.73% 11.9% 12% 12.9%
ROA (Net income/ Total Assets) - 10.5% 14.1% 9.24% 6.85% 8.02% 8.26% 9.77%
Assets 1 - 3,855 4,272 4,896 5,223 5,862 6,384 6,324
Book Value Per Share 2 18.60 20.50 26.30 - 31.50 35.00 38.50 42.10
Cash Flow per Share 2 3.440 4.910 6.850 4.010 3.740 6.350 6.630 7.130
Capex 1 273 278 290 287 338 387 398 416
Capex / Sales 10.19% 8.9% 8.59% 7.99% 9.21% 9.91% 9.5% 9.09%
Announcement Date 26/02/20 24/02/21 02/03/22 07/03/23 14/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
101.5 EUR
Average target price
112.8 EUR
Spread / Average Target
+11.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.3B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD. Stock Shanghai Runda Medical Technology Co., Ltd.
-8.80% 1.53B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. BIM Stock
  4. Financials bioMérieux